: Data on pregnancy outcome in alemtuzumab-treated women are scarce and derived from safety reports of clinical trials. We report on seven women with overall eight pregnancies during treatment with alemtuzumab in a real-world setting. All pregnancies occurred within 9 months after alemtuzumab treatment, and two of them within 4 months despite patients being informed on pregnancy prevention. We found one congenital cytomegalovirus infection, one spontaneous abortion, one elective abortion due to extrauterine pregnancy, and five live births without congenital abnormalities or birth defects.
Pregnancy outcomes in alemtuzumab treated women with multiple sclerosis: a case series / Russo, C. V.; Lanzillo, R.; Sacca, F.; Moccia, M.; Carotenuto, A.; Brescia Morra, V.. - In: NEUROLOGICAL SCIENCES. - ISSN 1590-3478. - 42:8(2021), pp. 3427-3430. [10.1007/s10072-020-04975-5]
Pregnancy outcomes in alemtuzumab treated women with multiple sclerosis: a case series
Russo C. V.;Lanzillo R.;Moccia M.;Carotenuto A.;Brescia Morra V.
2021
Abstract
: Data on pregnancy outcome in alemtuzumab-treated women are scarce and derived from safety reports of clinical trials. We report on seven women with overall eight pregnancies during treatment with alemtuzumab in a real-world setting. All pregnancies occurred within 9 months after alemtuzumab treatment, and two of them within 4 months despite patients being informed on pregnancy prevention. We found one congenital cytomegalovirus infection, one spontaneous abortion, one elective abortion due to extrauterine pregnancy, and five live births without congenital abnormalities or birth defects.| File | Dimensione | Formato | |
|---|---|---|---|
|
Pregnancy outcomes in alemtuzumab treated women with multiple.pdf
non disponibili
Tipologia:
Versione Editoriale (PDF)
Licenza:
Non specificato
Dimensione
155.69 kB
Formato
Adobe PDF
|
155.69 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
